SONN (Sonnet BioTherapeutics Holdings) ROC % : -1,536.85% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Sonnet BioTherapeutics Holdings ROC %?

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. Sonnet BioTherapeutics Holdings's annualized return on capital (ROC %) for the quarter that ended in Jun. 2024 was -1,536.85%.

As of today (2024-12-14), Sonnet BioTherapeutics Holdings's WACC % is 10.50%. Sonnet BioTherapeutics Holdings's ROC % is -738.16% (calculated using TTM income statement data). Sonnet BioTherapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Sonnet BioTherapeutics Holdings ROC % Historical Data

The historical data trend for Sonnet BioTherapeutics Holdings's ROC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sonnet BioTherapeutics Holdings ROC % Chart

Sonnet BioTherapeutics Holdings Annual Data

Trend

Sep19

Sep20

Sep21

Sep22

Sep23

ROC %

-573.45

-1,223.97

-1,316.90

-1,629.27

-794.13

Sonnet BioTherapeutics Holdings Quarterly Data
	Sep19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROC %	Get a 7-Day Free Trial														-603.58	-519.39	-268.49	-1,692.29	-1,536.85

Sonnet BioTherapeutics Holdings ROC % Calculation

Sonnet BioTherapeutics Holdings's annualized Return on Capital (ROC %) for the fiscal year that ended in Sep. 2023 is calculated as:

	ROC % (A: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (A: Sep. 2022 )	+	Invested Capital (A: Sep. 2023 ))	/ count )
=	-18.793 * ( 1 - 0% )	/	( (1.856	+	2.877)	/ 2 )
=	-18.793	/	2.3665
=	-794.13 %

where

	Invested Capital		(A: Sep. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.83	-	6.725	-	( 3.053	-	max(0, 8.165	-	5.414	+	3.053	))
=	1.856

	Invested Capital		(A: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.429	-	3.339	-	( 2.274	-	max(0, 5.525	-	4.738	+	2.274	))
=	2.877

Sonnet BioTherapeutics Holdings's annualized Return on Capital (ROC %) for the quarter that ended in Jun. 2024 is calculated as:

	ROC % (Q: Jun. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2024 )	+	Invested Capital (Q: Jun. 2024 ))	/ count )
=	-14.116 * ( 1 - 0% )	/	( (0.895	+	0.942)	/ 2 )
=	-14.116	/	0.9185
=	-1,536.85 %

where

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.909	-	2.556	-	( 3.786	-	max(0, 2.765	-	5.223	+	3.786	))
=	0.895

	Invested Capital		(Q: Jun. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.797	-	2.837	-	( 3.554	-	max(0, 3.11	-	5.128	+	3.554	))
=	0.942

Note: The Operating Income data used here is four times the quarterly (Jun. 2024) data.

Sonnet BioTherapeutics Holdings (NAS:SONN) ROC % Explanation

ROC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROIC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Sonnet BioTherapeutics Holdings's WACC % is 10.50%. Sonnet BioTherapeutics Holdings's ROC % is -738.16% (calculated using TTM income statement data). Sonnet BioTherapeutics Holdings earns returns that do not match up to its cost of capital. It will destroy value as it grows.

Be Aware

Like ROE % and ROA %, ROC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Sonnet BioTherapeutics Holdings ROC % Related Terms

Thank you for viewing the detailed overview of Sonnet BioTherapeutics Holdings's ROC % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sonnet BioTherapeutics Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sonnet BioTherapeutics Holdings Inc (NAS:SONN) » Definitions » ROC %

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Overlook Center, Suite 102, Princeton, NJ, USA, 08540

Website

https://www.sonnetbio.com

Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.

Executives

John Markey	10 percent owner	10096 RIDGEWOOD DRIVE, TWINSBURG OH 44087
Susan Dexter	officer: Chief Technical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Albert D. Dyrness	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Nailesh Bhatt	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Pankaj Mohan	director, officer: Chairman, President and CEO	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Lori Mcneill	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, SUITE 102, PRINCETON NJ 08540
Richard T Kenney	officer: Chief Medical Officer	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
Donald J. Griffith	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Terence Anthony Rugg	officer: Chief Medical Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
John K. Cini	officer: Chief Scientific Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Raghu Rao	director	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Cross John Harry Iii	officer: Chief Financial Officer	C/O SONNET BIOTHERAPEUTICS HOLDINGS, INC, 100 OVERLOOK CENTER, PRINCETON NJ 08540
Oz Rey Llc	10 percent owner	918 CONGRESS AVENUE, SUITE 100, AUSTIN TX 78701
Mv Amanth Llc	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701-3516
Robert Sumner Hersch	10 percent owner	515 CONGRESS AVE, STE 1400, AUSTIN TX 78701